News

Merck Animal Health will invest $895 million to expand vaccine manufacturing and R&D in Kansas, while Lilly is committing ...
Merck (NYSE:MRK) on Thursday announced plans to invest $895M to expand a manufacturing facility in Kansas, becoming the ...
As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the ...
A new manufacturing plant in De Soto will be a Center of Excellence for the global company, along with expanded R&D ...
Roche warned that President Trump's executive order on drug pricing threatens its planned $50 billion investment in the ...
Merck maintained its 2025 full-year revenue ... supported by a robust pipeline and significant investments in manufacturing and R&D. Management emphasized a focus on navigating short-term ...
The 470,000-square-foot facility will support the launch and commercial production of next-generation biologics and therapies ...
Merck (NYSE:MRK) is set to showcase significant research advancements, including updates on its KEYTRUDA indications at the upcoming ASCO Annual Meeting, which could enhance its oncology footprint.
Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...